The 8 highest-scored Medical Devices companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Leading the table: Ambu A/S (8/10), Anika Therapeutics, Inc. (6/10), Pulse Biosciences, Inc. (6/10).
| # | Company | Cyborg Score | The verdict | Ownership | Peers |
|---|---|---|---|---|---|
| 1 | Ambu A/S | 8/10 | Ambu is a well-positioned medical device leader with market-creating innovation in single-use endoscopy, strong North American exposure, and | Public | Competitors |
| 2 | Anika Therapeutics, Inc. | 6/10 | Strategic portfolio optimization driving commercial traction in high-growth regenerative solutions offset by regulatory setbacks in cartilag | Public | |
| 3 | Pulse Biosciences, Inc. | 6/10 | Early-stage bioelectric medicine innovator with unique technology platform and expanding clinical applications seeking path to profitability | Public | |
| 4 | Supermax Corporation Berhad | 6/10 | Stable but cyclical glove manufacturer with solid market position, though exposed to commodity pricing and industry overcapacity challenges. | Public | |
| 5 | PolyNovo Limited | 5/10 | Emerging biotech medical device company with proprietary polymer technology facing near-term margin pressures but positioned for long-term g | Public | |
| 6 | Know Labs, Inc. | 4/10 | High-risk medtech venture with differentiated technology undermined by pre-commercial status, financial distress, and strategic confusion fo | Public | |
| 7 | SeaStar Medical Holding Corporation | 3/10 | Early-stage biotech with validated technology but severely challenged market position and urgent need for clinical trial success and revenue | Public | |
| 8 | Talis Biomedical Corporation | 2/10 | A shell company in distress exploring strategic alternatives with uncertain viability as a standalone entity. | Public |
See also Medical Devices industry research and the full industry ratings index.
Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. How the score works · Methodology.